Backgrounds/Aims: Vitamin K may plays a role in controlling hepatocellular carcinoma (HCC) cell growth. In this study, we intended to present 5-year experience of 72 patients receiving oral vitamin K with or without sorafenib. Its end-point was to evaluate the safety of combination therapy using sorafenib and vitamin K. Methods: An interim analysis was performed as a single-arm cross-sectional study, including 72 HCC patients who underwent liver resection or transplantation and administered oral vitamin K2 alone (n=47) or with sorafenib (n=25). Results: In all patients, administration of vitamin K2 analog 45 mg/day did not show any noticeable adverse side-effect during vitamin K therapy of 23.3±10.6 months, except for one patient who experienced skin rash at the third day of vitamin K therapy. In 25 patients receiving sorafenib and vitamin K for 6 months or longer, any noticeable adverse side-effect suspected of vitamin K origin was not identified yet. A small proportion of patients showed unexpectedly favorable anti-tumor effects after use of vitamin K with or without sorafenib. Conclusions: Because add-on of oral vitamin K did not increase the adverse side-effects of sorafenib, a combination therapy with these two agents appears to be worthy of further clinical trial with an expectation of synergistic therapeutic effects. 
INTRODUCTION
The most common primary liver cancer, hepatocellular carcinoma (HCC), accounts for 70-85% of all liver cancers. Cancer progression is associated with an abrogation of the normal controls that limit cell migration and invasion, eventually leading to metastasis. The epithelial-mesenchymal transition (EMT) is proposed as a crucial step in promoting cell migration, tumor invasiveness and metastasis. EMT is a transient and reversible switch from a polarized, epithelial phenotype to a fibroblastic or mesenchymal cellular phenotype, the latter exhibiting highly motile and invasive properties. 1, 2 Vitamin K has the ability to prevent the development of HCC in women with viral cirrhosis. 3 A number of findings in vitro have indicated that vitamin K may play a role in controlling HCC growth. 4, 5 In the absence of vita- but it is suggested that HCC cells may shift to a DCP-producing phenotype when they gain migratory or invasive properties through EMT. 6 Sorafenib is a multikinase inhibitor that targets several serine/threonine and tyrosine receptor kinases. 7 Despite its therapeutic efficacy, sorafenib treatment in HCC patients causes DCP levels to increase, and paradoxically, the elevation of DCP may also indicate a highly therapeutic effect of sorafenib. 8, 9 This induction may represent tumor suppression due to the anti-angiogenic effects of sorafenib because hypoxia stimulation is known to impair vitamin K uptake and to induce DCP in HCC. 10 These findings led us to hypothesize that a synergistic therapeutic effect against HCC could be achieved by combining sorafenib with vitamin K treatment.
Clinically, we had administered oral vitamin K2 analog for HCC patients with an expectation of some anti-tumor effects. We experienced favorable outcomes in a few patients with metastatic HCCs, but meta-analyses including a randomized controlled study failed to prove its preventive and therapeutic effects. 11, 12 Currently, sorafenib is the only effect-proven therapeutic agent for patients with HCC lesions which are not manageable with loco-regional treatments, 13, 14 but its therapeutic response is often disappointing despite its adverse side-effects.
We have carried out two separate studies, one experimental in vitro study and one single-arm clinical study. In the experimental studies, we already demonstrated that sorafenib and vitamin K can function synergistically to inhibit the migration and proliferation of HCC cells. 15, 16 In this clinical study, we presented our 5-year experience of 72 patients receiving oral vitamin K2 with or without sorafenib. Its end-point was to evaluate the safety of combination therapy using sorafenib and vitamin K. In patients with HCC recurrence, DCP level was dramatically decreased close to the baseline values after vitamin K administration and maintained stably unless the recurrent HCC lesions progressed very aggressively.
MATERIALS AND METHODS

An
As being an interim analysis focused on only vitamin K-associated side-effects, the HCC recurrence and survival outcomes of these patients were not analyzed yet; instead we briefly presented two selected patients demonstrat-
Fig. 2.
A liver transplant recipient demonstrating vitamin K-associated anti-tumor effect on isolated pulmonary metastasis. A 58 year-old female recipient had isolated lung metastasis 18 months after transplantation, thus sorafenib and vitamin K were administered for 30 months. (A) Since lung mass progressed slowly, sorafenib was discontinued due to disease progression and only vitamin K was administered for more than 12 months. (B) The patient is currently doing well without any serious symptom despite very slow tumor progression. ing definite anti-tumor effect of vitamin K alone ( Fig. 1) and with sorafenib (Fig. 2) . ways has been suggested to hold great promise for preventing tumor cell growth. 21 We suggested that the syner- widely used for treatment of osteoporosis. 11, 12 We also found that vitamin K add-on to sorafenib did not increase the adverse side-effect of sorafenib. Interestingly, we observed exceptionally favorable outcomes in a small proportion of patients with HCC metastasis after vitamin K therapy alone or with sorafenib. Solitary administration of oral vitamin K to patients with metastatic HCC has sporadically led to a favorable outcome, but meta-analyses including a randomized controlled study failed to prove its anti-tumor effects. 11, 12 In conclusion, the results of our clinical study combined with precedent experimental studies support our assumption that supplementing sorafenib with vitamin K may produce synergistic therapeutic effects against HCC.
DISCUSSION
Because add-on of oral vitamin K did not increase the adverse side-effects of sorafenib, a combination therapy with these two agents appears to be worthy of further clinical trial with an expectation of synergistic therapeutic effects.
